Literature DB >> 16594620

Oligonucleotide-based antiviral strategies.

S Schubert1, J Kurreck.   

Abstract

In the age of extensive global traffic systems, the close neighborhood of man and livestock in some regions of the world, as well as inadequate prevention measures and medical care in poorer countries, greatly facilitates the emergence and dissemination of new virus strains. The appearance of avian influenza viruses that can infect humans, the spread of the severe acute respiratory syndrome (SARS) virus, and the unprecedented raging of human immunodeficiency virus (HIV) illustrate the threat of a global virus pandemic. In addition, viruses like hepatitis B and C claim more than one million lives every year for want of efficient therapy. Thus, new approaches to prevent virus propagation are urgently needed. Antisense strategies are considered a very attractive means of inhibiting viral replication, as oligonucleotides can be designed to interact with any viral RNA, provided its sequence is known. The ensuing targeted destruction of viral RNA should interfere with viral replication without entailing negative effects on ongoing cellular processes. In this review, we will give some examples of the employment of antisense oligonucleotides, ribozymes, and RNA interference strategies for antiviral purposes. Currently, in spite of encouraging results in preclinical studies, only a few antisense oligonucleotides and ribozymes have turned out to be efficient antiviral compounds in clinical trials. The advent of RNA interference now seems to be refueling hopes for decisive progress in the field of therapeutic employment of antisense strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16594620      PMCID: PMC7120703          DOI: 10.1007/3-540-27262-3_13

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  96 in total

Review 1.  The chemical repertoire of natural ribozymes.

Authors:  Jennifer A Doudna; Thomas R Cech
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

Review 2.  Mechanisms of gene silencing by double-stranded RNA.

Authors:  Gunter Meister; Thomas Tuschl
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

3.  Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions.

Authors:  Steffen Schubert; Arnold Grünweller; Volker A Erdmann; Jens Kurreck
Journal:  J Mol Biol       Date:  2005-05-13       Impact factor: 5.469

4.  Human immunodeficiency virus type 1 escape from RNA interference.

Authors:  Daniel Boden; Oliver Pusch; Frederick Lee; Lynne Tucker; Bharat Ramratnam
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction.

Authors:  Uwe Kühl; Matthias Pauschinger; Peter Lothar Schwimmbeck; Bettina Seeberg; Conny Lober; Michel Noutsias; Wolfgang Poller; Heinz-Peter Schultheiss
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

6.  Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells.

Authors:  Peter C Scacheri; Orit Rozenblatt-Rosen; Natasha J Caplen; Tyra G Wolfsberg; Lowell Umayam; Jeffrey C Lee; Christina M Hughes; Kalai Selvi Shanmugam; Arindam Bhattacharjee; Matthew Meyerson; Francis S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

7.  RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.

Authors:  Jirong Bai; Nirmal Banda; Nan Sook Lee; John Rossi; Ramesh Akkina
Journal:  Mol Ther       Date:  2002-12       Impact factor: 11.454

8.  Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme.

Authors:  J O Ojwang; A Hampel; D J Looney; F Wong-Staal; J Rappaport
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

Review 9.  Interfering with hepatitis C virus RNA replication.

Authors:  Glenn Randall; Charles M Rice
Journal:  Virus Res       Date:  2004-06-01       Impact factor: 3.303

10.  Modulation of HIV-1 replication by RNA interference.

Authors:  Jean-Marc Jacque; Karine Triques; Mario Stevenson
Journal:  Nature       Date:  2002-06-26       Impact factor: 69.504

View more
  6 in total

Review 1.  Ribonucleases as novel chemotherapeutics : the ranpirnase example.

Authors:  J Eugene Lee; Ronald T Raines
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

Review 2.  Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics.

Authors:  Burak Berber; Cihan Aydin; Fatih Kocabas; Gulen Guney-Esken; Kaan Yilancioglu; Medine Karadag-Alpaslan; Mehmet Caliseki; Melek Yuce; Sevda Demir; Cihan Tastan
Journal:  Gene Ther       Date:  2020-12-14       Impact factor: 5.250

Review 3.  Development and application of ribonucleic acid therapy strategies against COVID-19.

Authors:  Lin Ning; Mujiexin Liu; Yushu Gou; Yue Yang; Bifang He; Jian Huang
Journal:  Int J Biol Sci       Date:  2022-08-01       Impact factor: 10.750

4.  Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites.

Authors:  Martin R Jakobsen; Joost Haasnoot; Jesper Wengel; Ben Berkhout; Jørgen Kjems
Journal:  Retrovirology       Date:  2007-04-26       Impact factor: 4.602

5.  Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers.

Authors:  Slobodan Paessler; Rene Rijnbrand; David A Stein; Haolin Ni; Nadezhda E Yun; Natallia Dziuba; Viktoriya Borisevich; Alexey Seregin; Yinghong Ma; Robert Blouch; Patrick L Iversen; Michele A Zacks
Journal:  Virology       Date:  2008-05-12       Impact factor: 3.616

Review 6.  SERS-Based Biosensors for Virus Determination with Oligonucleotides as Recognition Elements.

Authors:  Oganes Ambartsumyan; Dmitry Gribanyov; Vladimir Kukushkin; Alexey Kopylov; Elena Zavyalova
Journal:  Int J Mol Sci       Date:  2020-05-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.